The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Heterogeneity of canonical prostate cancer markers across lesions in metastatic castration-resistant prostate cancer.
 
Anna S. Trigos
No Relationships to Disclose
 
Anupama Pasam
No Relationships to Disclose
 
Andrisha-Jade Inderjeeth
No Relationships to Disclose
 
Lachlan D. Cain
No Relationships to Disclose
 
Sirui Weng
No Relationships to Disclose
 
Vinita Gupta
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Beate Sable
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Katherine L. Paweletz
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Julie M. Bailis
Employment - Amgen
Stock and Other Ownership Interests - Amgen; Amgen
Patents, Royalties, Other Intellectual Property - I am an inventor on patents and patent applications from Amgen, Inc.
 
Yangyi Zhang
No Relationships to Disclose
 
Yuzhou Feng
No Relationships to Disclose
 
Angelyn Anton
Honoraria - Amgen; Eisai; Janssen-Cilag
Consulting or Advisory Role - Amgen
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Janssen (Inst); Mundipharma (Inst)
 
Ben Tran
Honoraria - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Janssen-Cilag; Pfizer; Sanofi; Tolmar
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; IQvia; Janssen-Cilag; MSD Oncology; Novartis; Pfizer/EMD Serono; Pfizer/EMD Serono; Roche Molecular Diagnostics; Sanofi; Tolmar
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb; Genentech (Inst); Ipsen; Janssen-Cilag (Inst); Merck Sharp & Dohme; Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma
 
Catherine Mitchell
No Relationships to Disclose
 
Shahneen Sandhu
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb/Roche (Inst); Genentech (Inst); Merck Sharp and Dohme (Inst); Novartis (Inst)
Speakers' Bureau - AstraZeneca (Inst); Bristol-Myers Squibb; Merck; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca (Inst); Endocyte/Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Senhwa Biosciences (Inst)
(OPTIONAL) Uncompensated Relationships - AAA/Endocyte/Novartis (Inst)